Table 8

Clinical trials on transjugular intrahepatic portosystemic shunt (TIPS) in patients with hepatorenal syndrome

Author

Year

N

Type of Study

Study Population

(n)

Pre-TIPS Cr

Post-TIPS cr

Survival


Brensing [135]

1997

16

Prospective uncontrolled

HRS Type 1 & 2

2.57 ± 1.59 mg/dl

1.18 ± 0.59 mg/dl

56%

Guevara [136]

1998

7

Prospective uncontrolled

HRS Type 1

5.0 ± 0.8 mg/dl

1.8 ± 0.4 mg/dl

28%

Mean survival: 140 ± 68 days

Brensing [137]

2000

41

Prospective

Non-TIPS (n = 10)HRS Type 1 (n = 7)

HRS Type 2 (n = 3)

2.3 ± 1.7 mg/dl

1.5 ± 1.2 mg/dl

Mean Survival:

TIPS: 92 ± 16 weeks

Non TIPS: 12 ± 8.5 weeks

TIPS (n = 31)

HRS Type 1 (n = 14)

HRS Type 2 (n = 17)

3 month survival

TIPS: 81%

Non TIPS:10%

Testino [138]

2003

18

Prospective uncontrolled

HRS Type 2 (n = 18)

1.9 ± 0.5 mg/dl

0.9 ± 0.3 mg/dl

67%: Transplanted


Nadim et al. Critical Care 2012 16:R23   doi:10.1186/cc11188

Open Data